基于前期细胞水平研究证实泽泻汤改善动脉粥样硬化（AS）进程中血管内皮细胞、巨噬细胞和平滑肌细胞的病理病化，并能调节LXRα脂代谢和炎性反应。近来研究提示SIRT1对LXRα去乙酰化调节其脂代谢和炎性反应，本项目拟利用活体AS转基因动物模型ApoE-/-小鼠为研究对象，通过不同剂量的泽泻汤干预动物,从外周血、大动脉、肝脏等部位，采用活体巨噬细胞体外进行脂质负荷培养，以血管壁的内皮细胞、巨噬细胞及血管平滑肌细胞多维度进行研究，探讨泽泻汤抗AS的作用，揭示其与SIRT1-LXRα通路的相关性；探讨同时利用小动物7.0T MR仪和USPIO示踪剂，动态观察泽泻汤对ApoE-/-小鼠AS的血管形态和血管斑块的影响以及观察斑块内巨噬细胞吞噬USPIO的能力，全面阐明泽泻汤抗AS的疗效，为经典古方泽泻汤抗AS的临床应用提供实验依据，为中医药抗AS研究提供思路。

Early study showed that Alisma Decoction improve the pathological change of vascular endothelial cells, macrophages and smooth muscle cells in the process of Atherosclerosis , based on LXRα regulating the lipid metabolism and inflammatory reaction; Recent research suggested that SIRT1 deacetylated LXRα and regulated the lipid metabolism and inflammatory reaction, so we use Alisma Decoction to intervene ApoE-/- AS mice, from peripheral blood, large artery, liver, abdominal cavity , In vitro lipid loaded macrophages culture, and the change of vascular endothelial cells, vascular macrophages and VSMCs in order to explore the mechanism of Alisma Decoction on AS and reveal the correlation with the SIRT1-LXRα pathway; To use of advanced small animal 7.0T MR and USPIO, dynamically observe the effect of Alisma Decoction on vascular morphology and vascular plaques of ApoE-/- AS mice model and observe the ability of macrophages swallow USPIO in plaques, comprehensively clarify the therapeutic effect of Alisma Decoction on AS and provide experimental basis for clinical application of classic prescription of Alisma Decoction of anti AS.